CDKN2B and open-angle glaucoma: These included examination of cases and controls from the United Kingdom, Japan, Australia, Canada, Netherland and a few consortia such as New Zealand Registry of Advanced Glaucoma (ANZRAG), Glaucoma Inheritance Study in Tasmania (GIST) and Wellcome Trust Case-Control Consortium 2/Blue Mountains Eye Study etc. A GWAS carried out in cases with advanced OAG from ANZRAG and the GIST identified susceptibility loci for POAG at TMCO1 and CDKN2B-AS[23].